Anemia, Iron and trace elements (23)

Anemia in Chronic Kidney Disease and Cancer- Use of Erythropoietin Analogues

Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

A randomized trial of intravenous and oral iron in chronic kidney disease

Latest trends and findings in international anemia management

Ferric Citrate: a phosphate binder that increases iron stores

Ferric citrate is associated with reduced healthcare costs: ESA and IV iron usage and hospitalizations

Evidence based medicine, real world evidence and emerging concepts in diabetic kidney disease

Webinar: Iron therapy in CKD- certainties and controversies

A randomized trial of intravenous and oral iron in chronic kidney disease

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients

Is Quality of Life a Sufficient Indicator for Initiation of ESA Therapy

Hepcidin and iron therapy in CKD

IMPROVING ESA THERAPY IN HEMODIALYSIS PATIENTS. INTERIM RESULTS OF A MULTI-CENTRE CLINICAL AUDIT

Erythroferrone: a hepcidin suppressor

Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target

Intravenous iron administration: new observations and time for the next steps

Pros and cons of giving ESAs in CKD patients

Recomendaciones de práctica clínica de la SLANH para el tratamiento de la anemia en el paciente con ERC

A Discussion of the KDIGO Anemia Guidelines audioicon

Anemia in CKD patients not on Dialysis